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Abstract
Background: ATP is an important signalling molecule in the peripheral and central nervous system. Both
glioma growth and tumor resection induces cell death, thus liberating nucleotides to the extracellular
medium. Nucleotides are hydrolyzed very slowly by gliomas when compared with astrocytes and induce
neuronal cell death and glioma proliferation. The objective of the present study was to test the
involvement of extracellular ATP in glioblastoma growth in a rat glioma model.
Methods: To deplete the extracellular ATP, the enzyme apyrase was tested on the treatment of gliomas
implanted in the rats CNS. One million glioma C6 cells in 3 microliters of DMEM/FCS were injected in the
right striata of male Wistar rats, 250–270 g. After 20 days, the rats were decapitated and the brain
sectioning and stained with hematoxylin and eosine. We performed immunohistochemical experiments
with Ki67, CD31 and VEGF. Total RNA was isolated from cultured glioma C6 cells and the cDNA was
analyzed by Real Time-PCR with primers for the NTPDase family.
Results: C6 glioma cells effectively have a low expression of all NTPDases investigated, in comparison
with normal astrocytes. The implanted glioma co-injected with apyrase had a significant reduction in the
tumor size (p < 0.05) when compared with the rats injected only with gliomas or with gliomas plus
inactivated apyrase. According to the pathological analysis, the malignant gliomas induced by C6 injection
and co-injected with apyrase presented a significant reduction in the mitotic index and other histological
characteristics that indicate a less invasive/proliferative tumor. Reduction of proliferation induced by
apyrase co-injection was confirmed by counting the percentage of Ki67 positive glioma cell nuclei.
According to counts with CD31, vessel density and neoformation was higher in the C6 group 20 days after
implantation. Confirming this observation, rats treated with apyrase presented less VEGF staining in
comparison to the control group.
Conclusion: These results indicate that the participation of extracellular ATP and the ecto-nucleotidases
may be associated with the development of this type of brain tumor in an in vivo glioma model.
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Background
Gliomas are a type of primary brain tumor that display an
extensive invasive behavior, but do not metastasize. The
growth and invasiveness into the surrounding normal
brain tissue makes gliomas a major challenge for clinical
intervention [1-3]. Therefore, the elucidation of the mech-
anisms involved in tumor growth, invasion and angiogen-
esis could aid in the treatment of these tumors.
The invasive cellular behavior of malignant gliomas is
determined by receptor mediated cell-substratum contacts
and cell-cell interaction, as well as cellular locomotion
[4]. Clues to the invasion process have been ascertained
through clarification of the key roles played by the extra-
cellular matrix (ECM), cell-adhesion molecules and
matrix degrading proteases [5].
Among other elements, vascular endothelial growth factor
(VEGF) is one of the most prominent angiogenic growth
factors. In fact, it has been shown that VEGF is secreted by
the C6 rat glioma cell line [6]. This growth factor is pro-
duced by almost all solid tumors and its receptors are
highly expressed on vascular endothelial cells and, pre-
dominantly, in vessels in the proximity of the tumor [7].
Moreover, some other systems may be involved in the
growth and invasion of the gliomas. Glutamate secreting
glioma cells demonstrate a growth advantage and glioma
cells release excitotoxic concentrations of glutamate, thus
killing neurons close to the tumor border and opening
space for tumor growth [8-10].
Another important signalling molecule that may be
involved in glioma development is ATP [11,12]. In glioma
C6 cells, ATP can bind and activate P2Y2, whereas its deg-
radation product, ADP, activate P2Y1 and P2Y12 recep-
tors [13-16].
In previous studies, we showed the involvement of the
purinergic system in glioma proliferation in different cell
types [17] and that glioma cells present a clear resistance
to death induced by cytotoxic concentrations of ATP when
compared with normal brain tissue [18]. Taken together
with its inability to metabolize extracellular ATP [19], the
purinergic system may form part of a novel and important
mechanism associated with the malignance of these
tumors.
ATP may be liberated into the extracellular space by the
excitotoxic death of the normal host cells and by the
injury caused by tumor resection, which is the mainstay of
initial therapy for gliomas [20]. We hypothesize that ATP
liberated under these conditions may, besides inducing
proliferation of the glioma itself, induce the cell death of
normal tissue and, consequently, increase the interstitial
space around the malignant glioma.
To test this hypothesis, we examined the effect of co-injec-
tion of apyrase, an ATP depleting enzyme, in a C6 rat gli-
oma experimental model, which has been extensively
used to test antitumoral interventions.
Methods
Cell culture
The C6 rat glioma cell line was obtained from the Ameri-
can Type Culture Collection (Rockville, Maryland,
U.S.A.). Cells were grown in culture flasks in Dulbecco's
Modified Eagle's medium (DMEM) with 5% fetal calf
serum (FCS) (Cultilab, Brazil).
Glioma implantation
Rat C6 glioma cells at around 70% confluency were
trypsinized, washed once in DMEM/5% FCS, spun down
and ressuspended in the same medium. A total of one mil-
lion cells in a volume of 3 µl were injected at a depth of
6.0 mm in the right striata (coordinates with regard to
bregma: 0.5 mm posterior and 3.0 mm lateral) of anesthe-
tized male Wistar rats, 250–270 g [9]. After 20 days, the
rats were decapitated and the entire brain was removed,
sectioned and fixed with 10% paraformaldehyde.
All the procedures were approved by the Ethical Commit-
tee of the Hospital de Clinicas de Porto Alegre.
Treatment with temozolomide
Ten days post-implantation, the rats were treated with 5
mg/Kg/day (i.p.) of temozolomide or DMSO (control
group of temozolomide) during 5 consecutive days. The
drug was dissolved in DMSO at a final concentration of
10% [21].
Co-injection of apyrase with C6 cells
Just before the injection, an apyrase (VII grade) (Sigma
Chemical Co., St. Louis, MO, USA) solution containing 2
U/ml was prepared in a C6 cell suspension in DMEM/FCS.
Cell viability was evaluated by trypan blue exclusion and
MTT assays. This preparation, containing C6 cells and
apyrase, was injected in 3 µl. An additional pulse of 3 µl
DMEM/FCS with apyrase was given within 1 min of the
first injection. As a control group, apyrase was denatured
by boiling for five minutes and was then injected together
with a C6 cell suspension using the same protocol
described above.
The enzyme activity of the injected apyrase was controlled
by measuring the hydrolysis of ATP and ADP in an incu-
bation medium containing 50 mM Tris.HCl, pH 7.5 and
1.5 mM CaCl2 and ATP or ADP as substrates to a final con-
centration of 1 mM, at 37°C. The reaction was stopped by
the addition of 0.2 ml of 10% TCA. The amount of inor-
ganic phosphate liberated was measured by the malachite
green method [22].BMC Cancer 2006, 6:226 http://www.biomedcentral.com/1471-2407/6/226
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Pathological analysis and tumor volume quantification
At least three hematoxylin and eosin (H&E) sections (4
µm thick, paraffin embedded) of each tumor were ana-
lyzed by two independent pathologists, blinded for the
experimental data. For tumor size quantification, images
were captured using a digital camera connected to the
microscope and analyzed using Image Tool Software™.
The total volume (mm3) of the tumor was computed by
summing the segmented areas and by the multiplication
of the slice resolution.
Immunohistochemical staining
Paraffin embedded, 5-mm formalin fixed tissue sections
were mounted on microscope slides. Tissue sections were
then dried overnight at 60°C, dewaxed in xylene and
rehydrated with distilled water. Endogenous peroxidase
was inhibited by 1% H2O2 in methanol for 10 min. Incu-
bation with the following antibodies was performed over-
night at room temperature: anti-Ki67 (1:20) (Dako, USA)
and anti-VEGF (1:400) (Dako, USA), followed by incuba-
tion with secondary antibody and Streptavidin-Avidin-
Biotin (Kit Lsab, Dako, USA). The peroxidase reaction was
performed using 3,3'diaminobenzidine tetrahydrochlo-
ride (DAB), according to the manufacturer's specifica-
tions. Finally, sections were counterstained with Harris
haematoxylin. Glioma cell proliferation was assessed by
counting the percentage of Ki67 positive glioma cell
nuclei in five independent high-magnification (×200)
fields per animal. Sections of rat spleen were used as pos-
itive controls.
To evaluate microvessel density, we used anti-CD31 mAb
(BD PharMingen, USA). The glioma sample specimens
were snap frozen in liquid nitrogen and cut into 4 µm sec-
tions. Frozen tissue was fixed in cold acetone (-20°C).
Subsequently, serial sections were stained with anti-CD31
mAb (1:30). The reaction was developed as described
above. The number of positive vessels/microscopic field
(×200) was counted. All samples were read blindly by two
independent readers, and the mean of their scores is pre-
sented.
Real time PCR analysis
Total RNA from cortical rat astrocytes or C6 glioma cells
was isolated from confluent cultures with RNA Mini Kit
(Qiagen) in accordance with the manufacturer's instruc-
tions. The cDNA species were synthesized with Super-
Script II (Life Technologies) from 5 µg of total RNA in a
total volume of 20 µl with both oligo (dT) primer and ran-
dom hexamers in accordance with the manufacturer's
instructions. SYRB Green I-based real-time PCR was car-
ried out using the MJ Research DNA Engine OpticonTM
Continuous Fluorescence Detection System (MJ Research
Inc., Walthan, MA), as described previously [23]. All PCR
mixtures contained: PCR buffer (final concentration: 10
mM Tris-HCl (pH 9.0), 50 mM KCl, 2 mM MgCl2, and
0.1% Triton X-100), 250 µM deoxy-NTP (Roche), 0.5 µM
of each PCR primer, 0.5× SYBR Green I (Molecular
Probes), 5% DMSO, and 1 U taq DNA polymerase
(Promega, Madison, WI) with 2 µl cDNA in a 25 µl final
volume reaction mix. The samples were loaded into wells
of Low Profile 96-well microplates. After an initial dena-
turation step for 1 min at 94°C, conditions for cycling
were 35 cycles of 30 sec at 94°C, 30 sec at 56°C, 1 min at
72°C. The fluorescence signal was measured right after
incubation for 5 sec at 79°C following the extension step,
which eliminates possible primer dimer detection. At the
end of the PCR cycles, a melting curve was generated to
identify specificity of the PCR product. For each run, serial
dilutions of human GAPDH plasmids were used as stand-
ards for quantitative measurement of the amount of
amplified DNA. In addition, for normalization of each
sample, hGAPDH primers were used to measure the
amount of hGAPDH cDNA. All samples were run in trip-
licate and the data were presented as a ratio of enzymes/
GAPDH. The set of primers used for NTPDase1 (CD39),
NTPDase2 (CD39L1), NTPDase3 (CD39L3), NTPDase5
(CD39L4) and NTPDase6 (CD39L2) were as described in
Vollmayer et al. (2001) [24]. Oligonucleotides were
obtained from Invitrogen. Negative controls were per-
formed with water as template and positive controls were
plasmids with cDNA sequences for mouse NTPDase1, rat
NTPDase2, and human NTPDase3, NTPDase5 and
NTPDase6.
Statistical analysis
Data were analyzed by one-way analysis of variance -
ANOVA, followed by Tukey-Kramer test. P values < 0.05
were taken to indicate statistical significance and means ±
SEM are presented.
Results
In the present study we tested the effect of the apyrase
enzyme on the growth of glioma cells in vivo. We have pre-
viously shown that C6 gliomas, a cell line that was origi-
nated from N-nitrosomethylurea-treated rats, exhibited
almost undetectable ATP and ADP-degrading activity;
however, our results did not allow the identification of
which NTPDase family members are expressed by these
cells [19]. To investigate which of the ecto-NTPDases are
present in the C6 glioma cell line, total RNA was isolated
from cultured glioma cells and the cDNA was analyzed by
Real Time-PCR with primers for the NTPDase family. Fig-
ure 1 shows that C6 cells effectively have a low expression
of all NTPDases investigated, in comparison with normal
astrocytes. We, therefore, chose the purified apyrase,
which hydrolyzes ATP and ADP at a similar rate to test our
hypothesis of the ATP participation in the process of gli-
oma invasion in host brain.BMC Cancer 2006, 6:226 http://www.biomedcentral.com/1471-2407/6/226
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The implanted tumors have characteristics that are closer
to those of human glioblastomas with the C6 cells grow-
ing in the intracerebral, intraventricular and intraparen-
chymal spaces (data not shown). Haematoxylin and eosin
examination showed that the implanted tumor has a high
mitotic index, nuclear pleomorphism, foci of tumor
necrosis, intratumoral hemorrhage and parenchymal
invasion (Table 1). In some cases, pathological analysis
identified pallisading cells delineating the foci of necrosis
and lymphocytic infiltration, with the occasional forma-
tion of edema fluid and neovascularization, which are
characteristics of glioblastoma multiforme in humans
(Table 1) (Fig. 3a and 3c).
In order to analyze whether the tumors implanted into
host brain were responsive to drugs that are clinically used
to treat gliomas and to validate our model, the rats were
treated with the alkylating agent, temozolomide [25]. In
Table 1: Characteristics of implanted gliomas.
Glioma (n = 9) Glioma + 
Apyrase (n = 8)
Coagulative necrosis 5/9 0/8
Intratumoral Hemorrhage 2/9 1/8
Lymphocytic infiltration 8/9 5/8
Peritumoral edema 5/9 1/8
Peripheric pseudopalisading 3/9 0/8
Mitotic index: mitosis/HPF 14.5 ± 4.7 8.4 ± 2.9*
The histological variables (coagulative necrosis, intratumoral 
hemorrhage, lymphocytic infiltration, peritumoral edema, peripheric 
pseudopalisading) were regarded as present or absent. Mitosis was 
counted in ten high power fields (HPF) of the periphery of the lesion, 
and the average of this counting was used as mitotic index. *P < 0.05, 
Students t-Test.
Comparison of NTPDase family expression in rat cortical astrocytes and rat C6 gliomas by quantitative real-time RT-PCR anal- ysis Figure 1
Comparison of NTPDase family expression in rat cortical astrocytes and rat C6 gliomas by quantitative real-time RT-PCR anal-
ysis. The expression of NTPDase members in astrocytes and C6 gliomas was quantitatively analyzed by real-time PCR as 
described in material and methods. C6: rat glioma cell line. Astr: cortical rat astrocytes. The results are presented as a ratio of 
cDNA enzymes/GAPDH.BMC Cancer 2006, 6:226 http://www.biomedcentral.com/1471-2407/6/226
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Tumor size of implanted gliomas Figure 2
Tumor size of implanted gliomas. Tumor size was measured 20 d after implantation of C6 cells in the different groups. (A) Rats 
were treated with 10% DMSO (vehicle control) or temozolomide in 10% DMSO (n = 5). (B) C6 cells were co-injected with: 
denaturated apyrase (C apyrase) or 2 U of apyrase (apyrase group) (n = 6). Data are means ± SEM. **p < 0.01; *p < 0.05 for 
comparison versus control, as determined by ANOVA, followed by Tukey-Krammer test.BMC Cancer 2006, 6:226 http://www.biomedcentral.com/1471-2407/6/226
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fact, tumor size analysis showed that the rats treated with
temozolomide presented a significant reduction in tumor
size when compared with the control groups (Fig. 2a). In
addition, rats treated with temozolomide survive signifi-
cantly longer than their respective controls, demonstrat-
ing a relative benefit of 100% in the rats' survival, that
means, at the time that 100% of control animals died all
animals from the treated group were still alive (data not
shown).
Confirming our purinergic hypothesis of glioma growth,
the results presented in Figure 2b show that the rats with
implanted glioma co-injected with apyrase had a signifi-
cant reduction in the tumor size (p < 0.05) in comparison
with the rats injected only with gliomas or with gliomas
plus inactivated apyrase, indicating that it is not the pres-
ence of the polypeptide, but the enzymatic activity that is
responsible for the effect of apyrase. The effect of apyrase
(2 U apyrase/106 cells) on C6 cell proliferation in culture
showed that the enzyme was not toxic to the cells but
instead, induced an increase by around 40% of the cell
number after 24 h of treatment. Additionally, the C6 cells
were detached from the surface handled exactly as for the
injection (with or without apyrase) and were subse-
quently re-plated in DMEM/FCS for 24 and 48 h. Cell via-
bility was analyzed by trypan blue exclusion and MTT
assays immediately after the cell preparation for injection
and after 24 and 48 h of culture. The cells presented more
than 90% viability when compared to the control cells in
all conditions tested, indicating that the effect of apyrase
The sections of implanted rat glioma were stained with haematoxylin and eosin (H&E) Figure 3
The sections of implanted rat glioma were stained with haematoxylin and eosin (H&E). Histological characteristics that define 
glioblastoma multiform as seen in rats implanted with gliomas (a,c) and in rats co-injected with apyrase (b,d). Necrosis (N) and 
microvascular proliferation (V), giant cell formation and nuclear pleomorphism (arrow). Scale bars = 100 µm (a,b); 20 µm (c,d).BMC Cancer 2006, 6:226 http://www.biomedcentral.com/1471-2407/6/226
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is not probably on the initial viability of the injected cells
but rather on the subsequent tumor implantation and
growth.
According to the pathological analysis, the malignant gli-
omas induced by C6 injection and co-injected with apy-
rase presented a significant reduction in the mitotic index
and other histological characteristics that indicate a less
invasive/proliferative tumor (Table 1). Less lymphocytic
infiltration and peritumoral edema were observed as well
as the absence of pseudopalisading necrosis (Fig. 4b and
4d). Reduction of proliferation induced by apyrase co-
injection was confirmed by counting the percentage of
Ki67 positive glioma cell nuclei (Table 2) (Fig. 4a and 4b).
Since tumor growth is dependent on the ability to induce
angiogenesis, we performed immunohistochemical
experiments with CD31. According to counts with CD31,
vessel density and neoformation was higher in the C6
group 20 days after implantation, in comparison with the
group co-injected with apyrase (Table 2). Confirming this
observation, the implanted gliomas with apyrase pre-
sented less VEGF staining in comparison to the control
group (glioma alone) (Fig. 4c and 4d).
Immunohistochemical stainings of gliomas Figure 4
Immunohistochemical stainings of gliomas. Glioma cell proliferation was assessed by immunostaining for Ki67 positive glioma 
cell nuclei (arrows) in rats implanted with gliomas (a) and in rats co-injected with apyrase (b). The sections were immunos-
tained for VEGF, in rats implanted with gliomas (c) and in rats co-injected with apyrase (d). Scale bars = 20 µm (a,b); 100 µm 
(c,d).BMC Cancer 2006, 6:226 http://www.biomedcentral.com/1471-2407/6/226
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Discussion
In the present study, we investigated the effect of the co-
injection of the enzyme apyrase with implanted C6 glio-
mas cells. It is well known that in vitro assays for growth
and invasion only represent isolated aspects of the multi-
cascade process of the in vivo tumor growth [4]. For this
reason, we decided to use an in vivo glioma model that,
despite its limitations, is useful for the study of growth,
angiogenesis and invasion of gliomas [3].
Extracellular ATP could be hydrolyzed by the action of a
cascade of enzymes, which includes the family of E-NTP-
Dases: NTPDase1 (CD39), NTPDase2 (CD39L1),
NTPDase3 (CD39L3), NTPDase5 (CD39L4) and
NTPDase6 (CD39L2) [26] and the more recently
described NTPDase7 and NTPDase8 [26-28]. Some of
these enzymes have been related with different tumors
[29-31] and recent studies demonstrated that NTPDase5
(CD39L4) is a proto-oncogene PCPH, which is involved
in tumor growth [32]. According to our results, the C6
cells present a very low expression of the NTPDase1
(CD39), NTPDase2 (CD39L1) and NTPDase3, the three
main enzymes involved in the cell surface ATP degrada-
tion when compared to astrocytes. Previous studies
showed that nucleotides and nucleosides induce prolifer-
ation in glioma cell lines [17] while ATP can mediate
death in dissociated primary cerebellar granules or striatal
neurons and in hippocampal organotypic cultures [33].
The indirect autocrine nature of this process should be
noted. The tumor induces, through the death of normal
cells, the release of more ATP that stimulates its own mul-
tiplication and, as a consequence, the cell death of other
cells opening space to be occupied by tumor cells and lib-
erating more ATP to continue the invasive process. Thus
we hypothesize that the re-establishment of NTPDase
activity may reduce glioma growth.
Purified apyrase is an enzyme widely used to deplete ATP
and hydrolyzes ATP and ADP at the same rate as
NTPDase1 [34]. Therefore, the apyrase may regulate the
extracellular nucleotide concentration and, thus, modu-
late their biological effects when activated by P2Y and P2X
receptors.
Our experiments demonstrate that the co-injection of apy-
rase significantly diminished the growth of implanted gli-
omas in rats after twenty days of tumor induction.
Considering that the injection of apyrase was done only at
the moment of implantation, the effect of ATP depletion
is probably at the implantation and initial growth of the
glioma. This could be of therapeutic interest, since the
application of apyrase in the surgical resection cavity
could be helpful in reducing the initial growth of invaded
tumor.
In addition to the reduction in the glioma size, patholog-
ical analysis demonstrated the lack of some important
malignant characteristics, typical of the glioblastomas, in
the tumors co-injected with apyrase (Table 1). Among
these, of note is the reduction of the mitotic index in the
rats treated with apyrase, indicating that ATP has an
important role in glioma proliferation in vivo. The partici-
pation of ADP in this process should not be excluded
since this nucleotide can bind to P2 receptors and is
potentially hydrolyzed by the injected apyrase.
As mentioned above, angiogenesis is an extremely impor-
tant process for sustained tumor growth. Studies have
demonstrated that C6 and human glioma cell lines secrete
VEGF [6,35,36]. Since invasive properties are largely
dependent on the presence of new vessels, CD31 was
studied and demonstrated a greater staining in the sam-
ples from rats implanted with the C6 cells in relation to
those co-injected with apyrase (Table 2). This result was
confirmed by the stronger VEGF staining in rats implanted
with glioma, when compared with the apyrase group (Fig.
4c and 4d). These results clearly indicate that microvascu-
lar proliferation is decreased in tumors treated with apy-
rase in relation to the control group, with a consequent
decrease in the blood flow in tumor areas with high cell
proliferation. The insufficient vascular supply may
become the limiting factor for tumor growth [7].
Conclusion
In conclusion, the data presented herein clearly show that
the presence of an ATP-depleting enzyme at the moment
of glioma implantation causes a significant decrease in the
growth, angiogenesis and proliferation index. The exact
mechanisms to explain these observations remain under
evaluation, however, the participation of ATP and the
ecto-nucleotidases may be associated with the develop-
ment of this type of brain tumor in an in vivo glioma
model.
Table 2: Immunohistochemical analysis of Ki67 and CD31 in rats 
implanted glioma.
Glioma Glioma + Apyrase
Ki67 # (n = 5) 48.7 ± 2.3 11.6 ± 7.9**
CD31 (n = 2) 96 ± 22.6 37.5 ± 3.5
# percentage of positive cells. Data are the means ± SEM
 Data are the means ± SEM for the number of vessels
**p < 0.01, Students t-test.BMC Cancer 2006, 6:226 http://www.biomedcentral.com/1471-2407/6/226
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